scholarly journals The ternary complex factor protein ELK1 is an independent prognosticator of disease recurrence in prostate cancer

The Prostate ◽  
2019 ◽  
Vol 80 (2) ◽  
pp. 198-208
Author(s):  
Luke Pardy ◽  
Rayna Rosati ◽  
Claire Soave ◽  
Yanfang Huang ◽  
Seongho Kim ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Ternary Complex ◽  
Disease Recurrence ◽  
Ternary Complex Factor

scholarly journals Promoter Methylation of PRKCB, ADAMTS12, and NAALAD2 Is Specific to Prostate Cancer and Predicts Biochemical Disease Recurrence

2021 ◽  
Vol 22 (11) ◽  
pp. 6091
Author(s):  
Kristina Daniunaite ◽  
Arnas Bakavicius ◽  
Kristina Zukauskaite ◽  
Ieva Rauluseviciute ◽  
Juozas Rimantas Lazutka ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
Promoter Methylation ◽  
Disease Recurrence ◽  
The Cancer Genome Atlas ◽  
Cancer Dataset ◽  
Protein Coding ◽  
Diagnosis And Prognosis ◽  
Genome Wide ◽  
Cancer Genome Atlas

The molecular diversity of prostate cancer (PCa) has been demonstrated by recent genome-wide studies, proposing a significant number of different molecular markers. However, only a few of them have been transferred into clinical practice so far. The present study aimed to identify and validate novel DNA methylation biomarkers for PCa diagnosis and prognosis. Microarray-based methylome data of well-characterized cancerous and noncancerous prostate tissue (NPT) pairs was used for the initial screening. Ten protein-coding genes were selected for validation in a set of 151 PCa, 51 NPT, as well as 17 benign prostatic hyperplasia samples. The Prostate Cancer Dataset (PRAD) of The Cancer Genome Atlas (TCGA) was utilized for independent validation of our findings. Methylation frequencies of ADAMTS12, CCDC181, FILIP1L, NAALAD2, PRKCB, and ZMIZ1 were up to 91% in our study. PCa specific methylation of ADAMTS12, CCDC181, NAALAD2, and PRKCB was demonstrated by qualitative and quantitative means (all p < 0.05). In agreement with PRAD, promoter methylation of these four genes was associated with the transcript down-regulation in the Lithuanian cohort (all p < 0.05). Methylation of ADAMTS12, NAALAD2, and PRKCB was independently predictive for biochemical disease recurrence, while NAALAD2 and PRKCB increased the prognostic power of multivariate models (all p < 0.01). The present study identified methylation of ADAMTS12, NAALAD2, and PRKCB as novel diagnostic and prognostic PCa biomarkers that might guide treatment decisions in clinical practice.

Salvage local treatment for localized radio-recurrent prostate cancer: a narrative review and future perspectives

2021 ◽  
Author(s):  
David Büchser ◽  
Rafael Medina ◽  
Esther Mayrata ◽  
Alba González ◽  
Marina Marban ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Local Treatment ◽  
Focus Ultrasound ◽  
Disease Recurrence ◽  
High Dose Rate ◽  
Narrative Review ◽  
High Dose ◽  
Treatment Techniques ◽  
Frequent Site ◽  
New Treatment

Although dose escalation protocols have improved biochemical control in prostate cancer radiotherapy, 10–45% of patients will experience disease recurrence. The prostate and seminal vesicles are the most frequent site of the first relapse. Traditionally, these patients have been managed with hormonal therapy, which is not curative. Recent improvements in diagnostic tests (e.g., multiparametric magnetic resonance and molecular imaging, including PET/CT scan with choline or Ga-PSMA) and new treatment techniques (e.g., stereotactic body radiation therapy or other minimally invasive alternatives like high-intensity focus ultrasound, cryoablation or high-dose-rate brachytherapy) offer new therapeutic strategies with the potential to cure some patients with limited adverse effects. In this narrative review, the authors present the most recent evidence to help identify the most suitable candidates for salvage treatment.

scholarly journals Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherapy

2014 ◽  
Vol 47 (2) ◽  
pp. 89-93 ◽  
Author(s):  
Carlos Antônio da Silva Franca ◽  
Sérgio Lannes Vieira ◽  
Antonio Carlos Pires Carvalho ◽  
Antonio Jose Serrano Bernabe ◽  
Antonio Belmiro Rodrigues Campbell Penna
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Biochemical Recurrence ◽  
Disease Free Survival ◽  
Disease Recurrence ◽  
Recurrence Rates ◽  
Psa Nadir ◽  
Group 2 ◽  
Iodine 125 ◽  
Group 1

Objective To evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients. Materials and Methods In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The results analysis was based on the definition of biochemical recurrence according to the Phoenix Consensus. Results Biochemical control was observed in 86 patients (71.7%), and biochemical recurrence, in 34 (28.3%). Mean PSAn was 0.53 ng/ml. The mean follow-up was 98 months. The patients were divided into two groups: group 1, with two year PSAn < 0.5 ng/ml after brachytherapy (74 patients; 61.7%), and group 2, with two year PSAn ≥ 0.5 ng/ml after brachytherapy (46 patients; 38.3%). Group 1 presented biochemical recurrence in 15 patients (20.3%), and group 2, in 19 patients (43.2%) (p < 0.02). The analysis of biochemical disease-free survival at seven years, stratified by the two groups, showed values of 80% and 64% (p < 0.02), respectively. Conclusion Levels of two year PSAn ≥ 0.5 ng/ml after brachytherapy are strongly correlated with a poor prognosis. This fact may help to identify patients at risk for disease recurrence.

A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer

1999 ◽  
Vol 161 (1) ◽  
pp. 354-355
Author(s):  
M.W. Kattan ◽  
J.A. Eastham ◽  
A.M.F. Stapleton ◽  
T.M. Wheeler ◽  
P.T. Scardino
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Disease Recurrence

scholarly journals African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men

2015 ◽  
Vol 33 (2) ◽  
pp. 70.e15-70.e22 ◽  
Author(s):  
Kosj Yamoah ◽  
Curtiland Deville ◽  
Neha Vapiwala ◽  
Elaine Spangler ◽  
Charnita M. Zeigler-Johnson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
African American Men ◽  
Disease Recurrence ◽  
Low Grade ◽  
Caucasian Men

scholarly journals Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review

2016 ◽  
Vol 69 (5) ◽  
pp. 802-820 ◽  
Author(s):  
Roderick C.N. van den Bergh ◽  
Niels J. van Casteren ◽  
Thomas van den Broeck ◽  
Eve R. Fordyce ◽  
William K.M. Gietzmann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Hormonal Treatment ◽  
Disease Recurrence ◽  
Curative Treatment
Sign in / Sign up

Export Citation Format

Share Document